Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction

Heart

Volumn 101, Issue 4, 2015, Pages 271-278

  Zhang, Yao Jun ^a   Iqbal, Javaid ^a,b   Windecker, Stephan ^c   Linke, Axel ^d   Antoni, Diethmar ^e   Sohn, Hae Young ^f   Corti, Roberto ^g   Van Es, Gerrit Anne ^h   Copt, Samuel ⁱ   Eerdmans, Pedro ⁱ   Saitta, Rana ⁱ   Morice, Marie Claude ^j   Di Mario, Carlo ^k   Juni, Peter ^c   Wijns, William ^l   Buszman, Pawel ^m   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^e KLINIKUM BOGENHAUSEN   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g KLINIK HIRSLANDEN   (Switzerland)

^h CARDIALYSIS   (Netherlands)

ⁱ Biosensors International Group Ltd   (Switzerland)

^j INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l OLV HOSPITAL   (Belgium)

^m Department of Cardiology Onze Lieve Vrouw Ziekenhuis ^*  (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; UMIROLIMUS; CARDIOVASCULAR AGENT; POLYMER;

ACUTE HEART INFARCTION; ADULT; ANGIOGRAPHY; ARTICLE; BIODEGRADABLE IMPLANT; BIOLIMUS ELUTING STENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT ORIENTED COMPOSITE ENDPOINT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SILENT MYOCARDIAL ISCHEMIA; SIROLIMUS ELUTING STENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SURGICAL RISK; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY THROMBOSIS; DEVICES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PREDICTIVE VALUE; PROSTHESIS; RECURRENT DISEASE; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921922831     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306359     Document Type: Article

References (30)

1. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293: 2908-17.
2. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435-45.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
4. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
5. Iqbal J, Sumaya W, Tatman V, et al. Incidence and predictors of stent thrombosis: a single-centre study of 5, 833 consecutive patients undergoing coronary artery stenting. EuroIntervention 2013; 9: 62-9.
6. Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009; 53: 1677-89.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62: 496-504.
8. Steg PG, Fox KA, Eagle KA, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-9.
9. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99: 1027-32.
10. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 977-87.
11. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012; 172: 611-21; discussion 21-2.
12. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482-90.
13. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-87.
14. Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012; 60: 381-7.
15. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 1370-6.
16. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163-73.
17. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-8.
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
19. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-104.
20. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-59.
21. Holmvang L, Kelbaek H, Kaltoft A, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv 2013; 6: 548-53.
22. Raber L, Kelbaek H, Taniwaki M, et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv 2014; 7: 355-64.
23. Sabate M, Raber L, Heg D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv 2014; 7: 55-63.
24. Pedersen SH, Pfisterer M, Kaiser C, et al. Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial. EuroIntervention 2014; 10: 58-64.
25. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011; 58: 1844-54.
26. Antonsen L, Thayssen P, Hansen HS, et al. Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. EuroIntervention 2014; 10: 212-23.
27. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis. Circulation 2007; 115: 1051-8.
28. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013; 6: 777-89.
29. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
30. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.